$285.60
Down 1.43% · live quote Sep 4, 2026
Market cap
$5.69B
Market cap $5.69B
Adjust assumptions
Adjust the usable peer mix to see how each valuation multiple moves the blended fair value.
Peer-implied fair value
$95.81
Blended value per share under the current mix.
Current price
$285.60
Sep 04, 2026
Peer gap
-66.5%
Peers imply 66.5% downside
Weighting mixer
Value contribution
4 peers →Price / Sales
$762.28M
Price / Earnings
$1.15B
Price / Sales
$1.52B
Price / Earnings
$2.30B
Equal-weight baseline
Premium 0.0%The simple average of every usable peer method, before your weighting adjustments.
Baseline equity value
$1.91B
Baseline / share
$95.81
Relative valuation prices this company against what the market already pays for its peers. For a cash-flow view that does not inherit peer sentiment, open the intrinsic model.
Spreadsheet data
Audit the saved peer set and the method inputs behind the blended fair value.
The saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market cap | Enterprise value | Revenue | EBITDA | Net income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
RPRX Royalty Pharma plc FY ended Dec 31, 2025 | $63.96 | $24.82B | — | $2.38B | $967.66M | $770.95M | 35.93x | 10.44x | — |
SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $22.50 | $2.38B | — | $2.20B | -$686.34M | -$713.41M | -3.16x | 1.08x | — |
INCY INCYTE CORP FY ended Feb 03, 2026 | $126.75 | $25.32B | — | $5.14B | $1.76B | $1.29B | 19.77x | 4.93x | — |
EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $59.01 | $14.62B | — | $2.32B | $975.59M | $782.57M | 21.23x | 6.30x | — |
RPRX
Royalty Pharma plc
$63.96
$24.82B
—
$2.38B
$967.66M
35.93x
10.44x
—
Cap $24.82BEV —Rev $2.38BEBITDA $967.66MP/E 35.93xP/S 10.44xEV/EBITDA —
SRPT
Sarepta Therapeutics, Inc.
$22.50
$2.38B
—
$2.20B
-$686.34M
-3.16x
1.08x
—
Cap $2.38BEV —Rev $2.20BEBITDA -$686.34MP/E -3.16xP/S 1.08xEV/EBITDA —
INCY
INCYTE CORP
$126.75
$25.32B
—
$5.14B
$1.76B
19.77x
4.93x
—
Cap $25.32BEV —Rev $5.14BEBITDA $1.76BP/E 19.77xP/S 4.93xEV/EBITDA —
EXEL
EXELIXIS, INC.
$59.01
$14.62B
—
$2.32B
$975.59M
21.23x
6.30x
—
Cap $14.62BEV —Rev $2.32BEBITDA $975.59MP/E 21.23xP/S 6.30xEV/EBITDA —
Which peer averages feed the weighted fair value, and which methods are excluded.
| Method | Type | Avg. multiple | Coverage | Implied equity value | Fair value / share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/4 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 5.69x | 4/4 | $1.52B | $76.47 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 18.44x | 4/4 | $2.30B | $115.14 | Included in the active peer mix. |
EV / EBITDA
EV · Enterprise Multiple
Avg. multiple
—
Coverage
0/4
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
Price / Sales
PS · Equity Multiple
Avg. multiple
5.69x
Coverage
4/4
Implied equity value
$1.52B
Fair value / share
$76.47
Included in the active peer mix.
Price / Earnings
PE · Equity Multiple
Avg. multiple
18.44x
Coverage
4/4
Implied equity value
$2.30B
Fair value / share
$115.14
Included in the active peer mix.
